JOHN FARMER to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications JOHN FARMER has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
2.244
-
The effect of statins on skeletal muscle function: the STOMP trial. Curr Atheroscler Rep. 2013 Aug; 15(8):347.
Score: 0.254
-
Aggressive statin therapy and the risk of malignancy. Curr Atheroscler Rep. 2013 Apr; 15(4):316.
Score: 0.248
-
Statins as adjunctive therapy in the management of hypertension. Curr Atheroscler Rep. 2010 Sep; 12(5):349-54.
Score: 0.207
-
The role of statin therapy in the management of cardiomyopathies. Curr Atheroscler Rep. 2009 Mar; 11(2):118-23.
Score: 0.187
-
Adjunctive interventions in myocardial infarction: the role of statin therapy. Curr Atheroscler Rep. 2008 Apr; 10(2):142-8.
Score: 0.175
-
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nat Clin Pract Cardiovasc Med. 2006 Dec; 3(12):664-72.
Score: 0.160
-
Benefits of atorvastatin in cholesterol lowering. Curr Atheroscler Rep. 2003 Mar; 5(2):94-5.
Score: 0.123
-
Statins and myotoxicity. Curr Atheroscler Rep. 2003 Mar; 5(2):96-100.
Score: 0.123
-
Learning from the cerivastatin experience. Lancet. 2001 Oct 27; 358(9291):1383-5.
Score: 0.112
-
Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000 Sep; 23(3):197-213.
Score: 0.104
-
Pleiotropic effects of statins. Curr Atheroscler Rep. 2000 May; 2(3):208-17.
Score: 0.101
-
Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol. 1998 Sep 24; 82(6A):26M-31M.
Score: 0.091
-
Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis. 1998 Sep-Oct; 41(2):71-94.
Score: 0.090
-
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther. 1992 Sep-Oct; 14(5):708-17.
Score: 0.060
-
Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant. 2005 Jan; 24(1):46-51.
Score: 0.035
-
Rationale for aggressive lipid lowering: evidence from clinical trials. Expert Rev Cardiovasc Ther. 2004 May; 2(3):305-9.
Score: 0.033
-
The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol. 2003 Jul 03; 92(1A):3i-9i.
Score: 0.032
-
Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002 Sep 24; 106(13):1595-8.
Score: 0.030
-
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999 Feb 16; 99(6):736-43.
Score: 0.023
-
Choosing the right lipid-regulating agent. A guide to selection. Drugs. 1996 Nov; 52(5):649-61.
Score: 0.020
-
Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf. 1994 Nov; 11(5):301-9.
Score: 0.017
-
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol. 1994 May 26; 73(14):42D-49D.
Score: 0.017